January 12 2021
Despite the challenges experienced in 2020, we are happy to report that the NRG Protocol Development Department coordinated the activation of 12 studies: 11 through CTEP and 1 through DCP (See table). The exciting news is that we have another 13 NCI-approved concepts that are in protocol development with activations anticipated in 2021 and 2022. There are 22 other concepts that were approved for future development during our four virtual or teleconference NRG Research Strategy Meetings held this past year. We are thankful to have a robust and diverse clinical trial portfolio and are excited about the new trial concepts we continue to receive from our dedicated committees and investigators.
As part of NRG Oncology’s ongoing efforts for performance improvements, the Protocol Development Committee has also partnered with the Protocol Operations and Management Committee to create a study principal investigator checklist/ toolkit to promote trial enrollment and to anticipate study accrual barriers. Look for this checklist/toolkit, which will roll-out sometime in 2021.
On behalf of NRG Oncology’s Research Strategy Committee’s leadership, we want to thank our study chairs, committee leaders and members, and our amazing staff for all their hard work and resulting success this past year. We look forward to an even better 2021!
Ronald D. Alvarez, MD
NRG Oncology Research Strategy Committee Chair
Jame Abraham, MD
NRG Oncology Research Strategy Committee Vice Chair
